Exelixis stock sees bullish signals on 15-minute chart with KDJ Golden Cross.

Exelixis's 15-minute chart has recently triggered a KDJ Golden Cross, as well as a Bullish Marubozu at 09/09/2025 15:30. This indicates a shift in momentum towards the upside and suggests the potential for further price appreciation. With buyers dominating the market, the bullish momentum is likely to persist.

On September 9, 2025, at 15:30, Exelixis Inc. (NASDAQ: EXEL) experienced a notable technical event on its 15-minute chart. The company's stock triggered a KDJ Golden Cross, accompanied by a Bullish Marubozu candlestick pattern, indicating a shift in momentum towards the upside and suggesting potential for further price appreciation. The buyers have taken control of the market, and it is likely that the bullish momentum will continue.

The KDJ Golden Cross, where the faster moving average crosses above the slower moving average, is a bullish signal in technical analysis. The Marubozu candlestick pattern, characterized by no shadows on the candlestick, further reinforces this positive trend. This pattern typically signifies strong buying pressure, suggesting that buyers have taken control of the market Exelixis's 15min chart triggered KDJ Golden Cross, Bullish ...^[1].

Exelixis, Inc. is a biotechnology company specializing in therapies for difficult-to-treat cancers. The company has been focused on developing and commercializing therapies for advanced renal cell carcinoma and medullary thyroid cancer, with its flagship product CABOMETYX (cabozantinib) driving growth in these areas. The company has also maintained a robust oncology pipeline, including candidates such as zanzalintinib and XL309. Despite recent revenue reports slightly below expectations for CABOMETYX, contributing to a modest stock decline, the company's pipeline development remains a key focus Exelixis's 15min chart triggered KDJ Golden Cross, Bullish ...^[1].

The company's decision not to pursue the Phase 3 portion of the STELLAR-305 trial for squamous cell carcinoma, opting instead for more commercially promising opportunities, reflects a strategic shift towards diversifying its portfolio beyond CABOMETYX. Ongoing Phase 1 studies for XL309, XB010, and XB628, along with FDA clearance for an IND application for XB371, indicate continued innovation and market leadership Exelixis's 15min chart triggered KDJ Golden Cross, Bullish ...^[1].

Collaborative partnerships, such as the one with Bristol-Myers Squibb for combination therapies in renal cell carcinoma, also support Exelixis, Inc.'s strategic growth. While the company's potential as an investment is acknowledged, certain AI stocks may offer greater upside potential and carry less downside risk Exelixis's 15min chart triggered KDJ Golden Cross, Bullish ...^[1].

Given the technical signals and strategic focus, investors may find Exelixis, Inc. an attractive option for further growth. However, as with any investment, it is crucial to conduct thorough research and consider both the technical and fundamental aspects of the company.

References:
Exelixis's 15min chart triggered KDJ Golden Cross, Bullish ...^[1] https://www.ainvest.com/news/exelixis-15min-chart-triggered-kdj-golden-cross-bullish-marubozu-signal-2509/
Becton Dickinson Gains 0.87% on KDJ Golden Cross and Marubozu as Volume Dips to $240M (440th Rank)^[2] https://www.ainvest.com/news/exelixis-strategic-leadership-shift-balancing-innovation-operational-continuity-oncology-2509/